Aprea Therapeutics, Inc. APRE
We are a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. Our approach focuses on matching treatments to specific cancer-related genetic mutations to potentially maximize effectiveness and minimize side effects. Specifically, we develop small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. We have assembled a team with extensive experience in the discovery, development, and commercialization of oncology drugs to support our mission of developing novel synthetic lethality-based cancer therapeutics.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D | — | — | — | — | $23.9M | $37.9M | $21.0M | $14.2M | $13.4M | — |
| SG&A | $6.5M | $6.5M | $8.4M | $21.0M | $13.6M | $14.9M | $8.6M | $2.3M | $2.5M | — |
| Total operating expenses | $13.5M | $15.8M | $16.1M | $113.4M | $37.4M | $52.8M | $29.5M | $16.5M | $15.9M | — |
| Operating income | -$13.2M | -$14.3M | -$15.5M | -$113.4M | -$37.4M | — | — | — | — | — |
| Pre-tax income | -$12.6M | -$13.0M | -$14.3M | -$112.7M | -$37.1M | -$53.5M | -$28.1M | -$15.5M | -$15.2M | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$12.6M | -$13.0M | -$14.3M | -$112.7M | -$37.1M | -$53.5M | -$28.1M | -$15.5M | -$15.2M | — |
| EPS, basic | -1.93 | -2.35 | -3.95 | -67.99 | -34.88 | -50.61 | -4.67 | — | — | — |
| EPS, diluted | -1.93 | -2.35 | -3.95 | -67.99 | -34.88 | -50.61 | -4.67 | -13.45 | -13.17 | — |
| Shares, diluted (wtd. avg.) | $6.5M | $5.5M | $3.6M | $1.7M | $1.1M | $1.1M | $6.0M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $14.6M | $22.8M | $21.6M | $28.8M | $53.1M | $89.0M | $130.1M | $65.7M | $24.4M | $13.7M |
| Total current assets | $15.6M | $23.6M | $22.5M | $30.2M | $56.6M | $92.4M | $133.0M | $66.0M | — | — |
| Property, plant and equipment | $59.8K | $81.5K | $88.4K | $2.3K | $23.9K | $38.5K | $41.6K | $24.4K | — | — |
| Total assets | $15.9M | $24.0M | $22.7M | $30.2M | $56.8M | $92.8M | $133.6M | $66.0M | — | — |
| Accounts payable | $713.7K | $1.4M | $1.7M | $842.8K | $1.8M | $4.5M | $2.2M | $1.7M | — | — |
| Total current liabilities | $2.8M | $3.4M | $4.4M | $3.2M | $7.3M | $15.3M | $9.1M | $4.9M | — | — |
| Total liabilities | — | — | — | $3.2M | $7.3M | $15.4M | $9.4M | $4.9M | — | — |
| Retained earnings | -$333.6M | -$321.0M | -$308.1M | -$293.8M | -$181.1M | -$144.0M | -$90.5M | -$62.5M | — | — |
| Total equity | $12.4M | $19.3M | $17.0M | $25.6M | $49.5M | $77.4M | $124.2M | -$51.4M | -$35.8M | -$21.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12.9M | -$13.6M | -$12.2M | -$25.0M | -$37.7M | -$41.8M | -$26.7M | -$15.3M | -$14.0M | — |
| Depreciation and amortisation | $21.7K | $22.3K | $7.1K | $4.4K | $12.8K | $28.8K | $11.1K | $8.3K | $7.9K | — |
| Capital expenditure | — | $15.5K | $93.1K | — | — | $25.7K | $30.9K | $3.7K | — | — |
| Investing cash flow | — | -$15.5K | -$93.1K | — | — | -$25.7K | -$30.9K | -$3.7K | — | — |
| Financing cash flow | $4.6M | $14.8M | $5.1M | $683.0K | $1.7M | $150.9K | $92.6M | $56.4M | $23.3M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-028068.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |